Drugs / WVE-007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06842186 | Jan 2025 → Dec 2027 expected | — | Wave Life Sciences USA, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | Wave Life Sciences USA, Inc. | Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases wavelifesciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WVE-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842186 ↗ |
| Modality | Small interfering RNA (siRNA) | “Stereopure siRNA oligonucleotide” NCT06842186 ↗ |
| Route | Subcutaneous | “when administered subcutaneously (SC)” NCT06842186 ↗ |